Glecaprevir/pibrentasvir ultra-short treatment to cure HCV infection: case report and literature review

Infez Med. 2020 Dec 1;28(4):616-620.

Abstract

Shortening therapy duration with direct-acting antiviral agents (DAAs) is desirable to pursue the WHO target of HCV eradication by 2030. We report two cases of HCV-infected women who achieved sustained virologic response after an ultra-short treatment with glecaprevir/pibrentasvir (G/P), discontinued due to cutaneous adverse events, and analyze similar cases reported in the literature. Female gender seems to be a prevailing characteristic in this group of patients. G/P, due to its pangenotypic and strong antiviral activity, may represent a candidate for a shortened DAA regimen in non-cirrhotic treatment-naive subjects.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aminoisobutyric Acids* / therapeutic use
  • Anti-Retroviral Agents / therapeutic use
  • Antiviral Agents* / therapeutic use
  • Benzimidazoles* / therapeutic use
  • Cyclopropanes* / therapeutic use
  • Drug Combinations
  • Female
  • Hepatitis C, Chronic* / drug therapy
  • Humans
  • Lactams, Macrocyclic* / therapeutic use
  • Leucine / analogs & derivatives*
  • Leucine / therapeutic use
  • Proline / analogs & derivatives*
  • Proline / therapeutic use
  • Pyrrolidines* / therapeutic use
  • Quinoxalines* / therapeutic use
  • Sulfonamides* / therapeutic use

Substances

  • Aminoisobutyric Acids
  • Anti-Retroviral Agents
  • Antiviral Agents
  • Benzimidazoles
  • Cyclopropanes
  • Drug Combinations
  • Lactams, Macrocyclic
  • Pyrrolidines
  • Quinoxalines
  • Sulfonamides
  • pibrentasvir
  • Proline
  • Leucine
  • glecaprevir